VRG
Miniprotein

Designing new therapeutic miniproteins, using our proprietary platform that combines AI-driven protein engineering and wet-lab directed evolution, we design therapeutic peptides with unprecedented potency and selectivity.

Stability

Stabilized by disulfide bonds
Resistant to protease degradation, hydrolysis and oxidation

Stability

Stabilized by disulfide bonds
Resistant to protease degradation, hydrolysis and oxidation

Developability

Precisely tunable PK/PD via modular fusions or sustained-release formulation
Low-cost, versatile manufacturing options: synthetic and recombinant

Developability

Precisely tunable PK/PD via modular fusions or sustained-release formulation
Low-cost, versatile manufacturing options: synthetic and recombinant

Efficacy

Outstanding (subnanomolar) affinity
Excellent tissue penetration due to small size (max 60 amino acids)

Efficacy

Outstanding (subnanomolar) affinity
Excellent tissue penetration due to small size (max 60 amino acids)

Safety

Extreme, up to 10,000x selectivity due to large interaction surface
No harmful breakdown products

Safety

Extreme, up to 10,000x selectivity due to large interaction surface
No harmful breakdown products

Low immunogenicity

No formation of anti-drug antibodies (ADAs) due to small size, and protease resistance

Low immunogenicity

No formation of anti-drug antibodies (ADAs) due to small size, and protease resistance

Chairman of the Board

Zalán Péterfi MD PhD

Director of Biologics Development

Zoltán Urbányi PhD

Senior Advisor

Natalia Novac PhD

R&D Director

Irena Adkins

Chief Financial Officer

Levente Lakatos

Strong leadership with impressive track record

VRG Miniprotein prides itself with 90+ years of Pharma R&D experience and multiple assets taken to clinical phase by its team members

Miniprotein prides itself with 90+ years of Pharma R&D experience and multiple assets taken to clinical phase by its team members

The Novamigra team brings over 100 years of combined pharmaceutical R&D experience, having successfully advanced 10 assets to the clinical phase and brought 2 to market.